Sentences with phrase «hiv vaccine regimen»

At the International AIDS Society conference in Paris, scientists announced that in an early - stage clinical trial, a new HIV vaccine regimen generated antibody responses in 100 percent of volunteers in most arms of the study.

The National Institutes of Health and partners have launched a large clinical trial to assess whether an experimental HIV vaccine regimen is safe and able to prevent HIV infection.

Collaborators are planning clinical testing of this HIV vaccine regimen in healthy adults at research sites in the U.S., East Africa, South Africa, and Thailand.

• RV217 (ECHO): HIV - 1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa • Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities • Karolinska Institute vaccine study in Tanzania testing a prime - boost HIV vaccine regimen using unadjuvanted DNA vaccines followed by a Modified Vaccinia Ankara (MVA), which was developed by MHRP and NIAID.

«Novel HIV vaccine regimen provides robust protection in non-human primates.»

Research Trials The HVTN also plans to test other HIV vaccine regimens in Southern Africa in a parallel research track using multiple vaccine candidates.

Not exact matches

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.

An HIV - 1 version of the promising vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study.

Based on these pre-clinical data, the HIV - 1 version of this vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Dr. Schief's work focuses on computation - guided and structure - based design of immunogens and immunization regimens, with the goal of inducing broadly neutralizing antibodies against HIV and other pathogens that have frustrated traditional vaccine design strategies.

This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program - led RV144 clinical trial in Thailand — the first study to demonstrate that a vaccine can protect people from HIV infection.

Results from an initial study to ensure that the RV144 vaccine regimen is safe and well - tolerated in South African volunteers were reported at the 2014 HIV Research for Prevention (R4P) conference.

The HIV Vaccine Trial Network (HVTN) plans to conduct clinical trials in heterosexual adults that will evaluate a prime - boost vaccine regimen similar to that used in RV144 adjusted to target the most common subtype of HIV in the region (subtVaccine Trial Network (HVTN) plans to conduct clinical trials in heterosexual adults that will evaluate a prime - boost vaccine regimen similar to that used in RV144 adjusted to target the most common subtype of HIV in the region (subtvaccine regimen similar to that used in RV144 adjusted to target the most common subtype of HIV in the region (subtype C).

2017 — Began a new multi-site Phase 2 Ebola vaccine study at MHRP sites in Africa evaluating a prime - boost regimen in both healthy and HIV - infected volunteers (Ad26.ZEBOV from J&J; MVA - BN - Filo from Bavarian Nordic)

The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical trial to evaluate the safety and immunogenicity of a prime - boost Ebola vaccine regimen in both healthy and HIV - infected volunteers.

At the first plenary session of AIDS Vaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infVaccine 2011, which opened this morning in Bangkok, Thailand, researchers presented the results of a two - year - long effort to try to identify an immunological explanation for the modest 31 % efficacy afforded by the prime - boost vaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infvaccine regimen tested in the RV144 trial, the first to show any efficacy in protecting against HIV infection.

The new Ad26 / MVA and Ad35 / Ad26 vector - based vaccine regimens resulted in over 80 % reduction in the per - exposure probability of acquisition of infection against repetitive challenges of SIV, a virus similar to HIV that infects monkeys.